Erase the trace: new frontiers in scar prevention and skin repair

Shi Fu; Niharika Singh; Shiffoni Sukhlal; Huiting Luo; Divleen K. Singh; Mimi R. Borrelli; Duc Bui; Sami Khan; Alexander B. Dagum; Gurtej Singh

doi:10.55092/bm20240009

Erase the trace: new frontiers in scar prevention and skin repair

Shi Fu
, Niharika Singh
, Shiffoni Sukhlal
, Huiting Luo
, Divleen K. Singh
, Mimi R. Borrelli
, Duc Bui
, Sami Khan
, Alexander B. Dagum
, Gurtej Singh

Surgery

Stony Brook University

Research output: Contribution to journal › Article › peer-review

Abstract

The management of scarring continues to be significant in health care due to their ubiquity and impact on daily life. Scars include immature, mature, atrophic, hypertrophic, and keloid scars, with hypertrophic and keloid scars commonly being targeted for therapeutic interventions. Hypertrophic and keloid scars have dysregulated wound healing phases, involving higher levels of inflammatory markers, such as TGF-β, PDGF, VEGF, as well as increased type 1 collagen. Current treatments for hypertrophic scarring and keloid scars include pressure garments, corticosteroids, laser therapy, scar excision, and radiation. The next steps in therapy involve minimizing scars and eventually eliminating scars by tissue regeneration; current research is exploring the inhibition of Yes-associated protein and harnessing TGF-β3 to support tissue regeneration over scarring in humans.

Original language	English
Article number	0009
Journal	Biofunctional Materials
Volume	2
Issue number	2
DOIs	https://doi.org/10.55092/bm20240009
State	Published - 2024

Keywords

scar prevention
scars
skin regeneration

Access to Document

10.55092/bm20240009

Cite this

@article{a64555f1d0e0422e9efa651220dfd7c3,

title = "Erase the trace: new frontiers in scar prevention and skin repair",

abstract = "The management of scarring continues to be significant in health care due to their ubiquity and impact on daily life. Scars include immature, mature, atrophic, hypertrophic, and keloid scars, with hypertrophic and keloid scars commonly being targeted for therapeutic interventions. Hypertrophic and keloid scars have dysregulated wound healing phases, involving higher levels of inflammatory markers, such as TGF-β, PDGF, VEGF, as well as increased type 1 collagen. Current treatments for hypertrophic scarring and keloid scars include pressure garments, corticosteroids, laser therapy, scar excision, and radiation. The next steps in therapy involve minimizing scars and eventually eliminating scars by tissue regeneration; current research is exploring the inhibition of Yes-associated protein and harnessing TGF-β3 to support tissue regeneration over scarring in humans.",

keywords = "scar prevention, scars, skin regeneration",

author = "Shi Fu and Niharika Singh and Shiffoni Sukhlal and Huiting Luo and Singh, \{Divleen K.\} and Borrelli, \{Mimi R.\} and Duc Bui and Sami Khan and Dagum, \{Alexander B.\} and Gurtej Singh",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors. Published by ELSP.",

year = "2024",

doi = "10.55092/bm20240009",

language = "English",

volume = "2",

journal = "Biofunctional Materials",

issn = "2959-0574",

number = "2",

}

TY - JOUR

T1 - Erase the trace

T2 - new frontiers in scar prevention and skin repair

AU - Fu, Shi

AU - Singh, Niharika

AU - Sukhlal, Shiffoni

AU - Luo, Huiting

AU - Singh, Divleen K.

AU - Borrelli, Mimi R.

AU - Bui, Duc

AU - Khan, Sami

AU - Dagum, Alexander B.

AU - Singh, Gurtej

PY - 2024

Y1 - 2024

N2 - The management of scarring continues to be significant in health care due to their ubiquity and impact on daily life. Scars include immature, mature, atrophic, hypertrophic, and keloid scars, with hypertrophic and keloid scars commonly being targeted for therapeutic interventions. Hypertrophic and keloid scars have dysregulated wound healing phases, involving higher levels of inflammatory markers, such as TGF-β, PDGF, VEGF, as well as increased type 1 collagen. Current treatments for hypertrophic scarring and keloid scars include pressure garments, corticosteroids, laser therapy, scar excision, and radiation. The next steps in therapy involve minimizing scars and eventually eliminating scars by tissue regeneration; current research is exploring the inhibition of Yes-associated protein and harnessing TGF-β3 to support tissue regeneration over scarring in humans.

AB - The management of scarring continues to be significant in health care due to their ubiquity and impact on daily life. Scars include immature, mature, atrophic, hypertrophic, and keloid scars, with hypertrophic and keloid scars commonly being targeted for therapeutic interventions. Hypertrophic and keloid scars have dysregulated wound healing phases, involving higher levels of inflammatory markers, such as TGF-β, PDGF, VEGF, as well as increased type 1 collagen. Current treatments for hypertrophic scarring and keloid scars include pressure garments, corticosteroids, laser therapy, scar excision, and radiation. The next steps in therapy involve minimizing scars and eventually eliminating scars by tissue regeneration; current research is exploring the inhibition of Yes-associated protein and harnessing TGF-β3 to support tissue regeneration over scarring in humans.

KW - scar prevention

KW - scars

KW - skin regeneration

UR - https://www.scopus.com/pages/publications/105032560719

U2 - 10.55092/bm20240009

DO - 10.55092/bm20240009

M3 - Article

AN - SCOPUS:105032560719

SN - 2959-0574

VL - 2

JO - Biofunctional Materials

JF - Biofunctional Materials

IS - 2

M1 - 0009

ER -

Erase the trace: new frontiers in scar prevention and skin repair

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this